GSK Advair launch
Executive Summary
GlaxoSmithKline 2,300 Advair sales reps visited 70,000 physicians "at least once" during asthma product's first week on market, CEO J.P. Garnier reports. The physician base represents 80% of asthma prescriptions. In the two weeks prior to the beta agonist/corticosteroid therapy launch, GSK generated 19,800 prescriptions, with 15,400 from the week ending April 13, Garnier adds
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: